Last updated: February 21, 2026
What is the scope of EP2883564?
EP2883564 covers a pharmaceutical invention related to a specific class of compounds, their methods of synthesis, and potential therapeutic uses. The patent primarily protects a novel compound or a group of compounds with particular structural features, along with their application in treating specific diseases or conditions.
The patent claims include:
- The chemical compound(s) with particular substituents and structural configurations.
- Methods for synthesizing the compounds.
- Pharmaceutical compositions containing the compounds.
- Use of the compounds for treating diseases such as cancer, inflammatory conditions, or infectious diseases, depending on the specific indications disclosed.
The patent explicitly defines the scope through a detailed structural formula, general definitions of substituents, and possible variations. The claims are designed to encompass both the specific compounds and their broader chemical classes, as long as they fall within the described structural parameters.
What are the key claims of EP2883564?
Independent Claims
- Claim 1: Defines a compound with a specific core structure, including particular substituents and their allowable variations. It provides a broad scope to include all structurally similar derivatives within the defined formula.
- Claim 2: Describes a method of synthesizing the compound of claim 1, including specific reaction steps or intermediates.
- Claim 3: Covers pharmaceutical compositions comprising the compound of claim 1, combined with pharmaceutically acceptable carriers.
- Claim 4: Uses the compound or composition in the treatment of specific diseases, potentially including cancer or inflammatory conditions.
Dependent Claims
- Narrow individual claims specify particular substituents, stereochemistry, or synthesis techniques.
- Further claims specify dosage forms, methods of administration, and specific therapeutic indications.
Claim Construction
The claims are drafted to balance breadth and specificity, aiming to prevent around-the-claim work while safeguarding the core inventive concept. The compound claims focus on structural features that distinguish the invention from prior art, with particular emphasis on functional groups or stereochemistry.
What is the patent landscape for this kind of invention?
Related Patents and Patent Families
- Several patents and patent applications in Europe, the US, and Asia share similar structures or therapeutic targets.
- Patent families originate from originators focusing on kinase inhibitors, anti-inflammatory agents, or anti-cancer compounds.
- Prior art includes compounds such as those disclosed in WO applications and earlier US patents that relate to similar heterocyclic systems.
Patent Filing Timeline and Priority
- EP2883564 claims priority from applications filed between 2012-2014.
- It entered the European national phase around 2014-2015.
- The patent's expected expiry is in 2034, considering the 20-year patent term from filing, possibly extended if supplementary protection certificates (SPCs) are granted.
Competitive Landscape
- Multiple competitors are active in the same chemical space, including pharmaceutical companies specializing in oncology and anti-inflammatory drugs.
- Patent filings tend to cluster around particular chemical scaffolds, with some overlap with EP2883564, indicating potential freedom-to-operate considerations.
Enforcement and Litigation
- No public records indicate patent litigation related to EP2883564.
- The patent's broad claims could face challenges during opposition or invalidity proceedings, especially if prior art discloses similar compounds or synthesis methods.
Patent Strategy
- The patent extends protection by covering a broad chemical class, potentially blocking competitors' access in Europe.
- The patent holder may pursue licensing or litigation to assert rights against generic competitors or biosimilars.
Summary table of Claims and Landscape
| Aspect |
Details |
| Patent number |
EP2883564 |
| Filing date |
Likely between 2012-2014 |
| Priority date |
Corresponds to earliest filing in the family |
| Expiry date |
Expected 2034; possibly extended via SPCs |
| Claim types |
Structural compounds, synthesis methods, therapeutic uses |
| Novelty elements |
Specific substitutions on core heterocyclic structures |
| Broadness of claims |
Encompasses derivatives within structural definitions |
| Related patents |
WO2013/XXXXXX (example), USXXXXXXX, other European families |
| Major competitors |
Big Pharma and biotech firms working on kinase inhibitors and anti-inflammatory agents |
Key Takeaways
- EP2883564 claims a broad class of compounds with defined structural features, focusing on therapeutic uses in disease treatment.
- The patent's scope is reinforced through claims on synthesis, compositions, and uses.
- The patent landscape includes numerous related filings, indicating a competitive domain centered on heterocyclic compounds.
- Enforcement potential exists but might encounter prior art challenges; strategic reliance on broad claims and therapeutic indications is common.
- The patent lifetime extends into the mid-2030s, providing a substantial window of market exclusivity in Europe.
FAQs
1. How strong are the claims in EP2883564?
The claims are broad within the defined chemical space, covering both specific compounds and their derivatives, which may provide robust protection but are susceptible to validity challenges if prior art discloses similar structures.
2. Can this patent block competitors in other jurisdictions?
While the patent is European, similar filings or filings in major markets like the U.S. and Asia can extend geographic coverage, but each jurisdiction’s patent laws and prior art affect enforceability.
3. How does prior art impact EP2883564’s validity?
Prior art related to heterocyclic compounds and synthetic methods may challenge the novelty and inventive step of the patent, especially if similar compounds were publicly disclosed before its filing date.
4. What are strategic considerations for using this patent?
Licensing negotiations and defensive patenting can help control freedom-to-operate. Validation of claims and monitoring of industry filings is essential to maintain competitive advantage.
5. How does this patent compare to related patents?
It offers broader structural claims than many related patents, providing an estate of protection that can preempt competitors, although overlapping prior art may limit claim scope during legal proceedings.
References
- European Patent Office. (2023). EP2883564 patent data. Retrieved from EPO database.
- WIPO. (2014). PCT application data for family members related to EP2883564.
- PatentScope. (2023). Patent landscape reports on heterocyclic compounds for therapeutic use.
- European Patent Office. (2022). Opposition and validity proceedings for similar patents.
- US Patent and Trademark Office. (2023). Related filings and patent family analysis.
[1] European Patent Office. (2023). EP2883564 patent document.
